176 related articles for article (PubMed ID: 9769840)
21. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
Martin WH; Delbeke D; Patton JA; Sandler MP
Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
[TBL] [Abstract][Full Text] [Related]
23. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
[TBL] [Abstract][Full Text] [Related]
24. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
25. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
[TBL] [Abstract][Full Text] [Related]
26. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
[TBL] [Abstract][Full Text] [Related]
27. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
[TBL] [Abstract][Full Text] [Related]
28. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies.
Torizuka T; Zasadny KR; Recker B; Wahl RL
Radiology; 1998 Jun; 207(3):767-74. PubMed ID: 9609902
[TBL] [Abstract][Full Text] [Related]
29. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
31. Impact of body habitus on quantitative and qualitative image quality in whole-body FDG-PET.
Tatsumi M; Clark PA; Nakamoto Y; Wahl RL
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):40-5. PubMed ID: 12483408
[TBL] [Abstract][Full Text] [Related]
32. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.
Stafford SE; Gralow JR; Schubert EK; Rinn KJ; Dunnwald LK; Livingston RB; Mankoff DA
Acad Radiol; 2002 Aug; 9(8):913-21. PubMed ID: 12186440
[TBL] [Abstract][Full Text] [Related]
33. [Imaging of cancer using positron emission tomography].
Goldman S; Vanderhoeft A; Lebeau de Hemricourt E; Dusart M; Damhaut P; Wikler D
Rev Med Brux; 1999 Sep; 20(4):A365-8. PubMed ID: 10523925
[TBL] [Abstract][Full Text] [Related]
34. Application of PET and PEt/CT imaging for cancer screening.
Chen YK; Ding HJ; Su CT; Shen YY; Chen LK; Liao AC; Hung TZ; Hu FL; Kao CH
Anticancer Res; 2004; 24(6):4103-8. PubMed ID: 15736459
[TBL] [Abstract][Full Text] [Related]
35. Nuclear imaging of bone tumors: FDG-PET.
Aoki J; Inoue T; Tomiyoshi K; Shinozaki T; Watanabe H; Takagishi K; Endo K
Semin Musculoskelet Radiol; 2001 Jun; 5(2):183-7. PubMed ID: 11500164
[TBL] [Abstract][Full Text] [Related]
36. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
Giorgetti A; Volterrani D; Mariani G
Radiol Med; 2002 Apr; 103(4):293-318. PubMed ID: 12107381
[TBL] [Abstract][Full Text] [Related]
37. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results.
Schiesser M; Stumpe KD; Trentz O; Kossmann T; Von Schulthess GK
Radiology; 2003 Feb; 226(2):391-8. PubMed ID: 12563131
[TBL] [Abstract][Full Text] [Related]
38. [Cancer detection with whole-body FDG PET images without attenuation correction].
Yasuda S; Ide M; Takagi S; Shohtsu A; Mitomi T; Kobayashi S; Suzuki Y
Kaku Igaku; 1996 Apr; 33(4):367-73. PubMed ID: 8683875
[TBL] [Abstract][Full Text] [Related]
39. [18F-FDG whole-body positron-emission tomography (PET) in patients with unknown primary tumors].
Matheja P; Schober O
Strahlenther Onkol; 2000 Mar; 176(3):151-2. PubMed ID: 10742838
[No Abstract] [Full Text] [Related]
40. [Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
Comans EF; Hoekstra OS; Hoekman K; van der Hoeven JJ; Golding RP; Teule GJ
Ned Tijdschr Geneeskd; 2000 Aug; 144(32):1520-8. PubMed ID: 10949634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
